Diabetes is a worldwide pandemic calling for innovation in therapeutic prevention and cure. Mounting evidence attribute the involvement of multiple immune dysfunctions in both type 1 diabetes (T1D, caused by autoimmunity) and type 2 diabetes (T2D, caused by insulin resistance).
"Stem Cell Educator therapy" is the innovative technology developed by Dr. Yong Zhao that uses stem cells drawn from human cord blood to targets autoimmune diseases. Currently, Tianhe is focusing on the application of Stem Cell Educator therapy in diabetes. Our clinical data provide powerful evidence that Stem Cell Educator therapy can balance the immune system and lead to the regeneration of islet beta cells and improve metabolic control in long-standing diabetic subjects. This groundbreaking technology is taking steps towards the ultimate cure of diabetes and revolutionizing the treatment of other autoimmune-related diseases.
Tianhe Stem Cell Biotechnologies Inc. has licensed a series of patented technologies from the isolation of human cord blood-derived multipotent stem cells (CB-SCs) to clinical applications. It has a major division in China, Jinan Tianhe Stem Cell Biotechnology Co., Ltd., located in Jinan High-tech Bioindustry Park District.
March 31, 2014 - The FDA-registered cord blood bank CORD:USE in Orlando (USA) and Tianhe Stem Cell Biotechnologies sign a Long-Term Partnership from current academic collaboration to future business collaboration on Stem Cell Educator therapy in clinic.
January 25, 2014 - Tianhe’s international patent on human cord blood
stem cells has been granted by European Patent Office. This patent will cover
the countries in European Union.